[Electrophysiological anti-arrhythmia effects of tiracizine in ventricular tachycardia].
The electrophysiologic effects and antiarrhythmic efficacy of tiracizine, a new class I antiarrhythmic drug, were studied in 16 patients with documented sustained ventricular tachycardia (VT) after intravenous drug application and in 6 patients after oral drug administration by means of programmed ventricular stimulation (PVS). After intravenous tiracizine (0.3 mg/kg) the VT was no longer inducible by PVS in 3 of 16 patients and became nonsustained in another patient. In 11 of 13 patients with further inducible VT the cycle duration of VT increased after tiracizine (mean 29 ms). After oral tiracizine (150-225 mg/day) the VT induction was suppressed in one patient. In a second patient the VT became nonsustained. Cycle length of VT in 4 patients with persistent induction of VT was longer after therapy (mean 88 ms). Antiarrhythmic efficacy of intravenous or oral tiracizine can be expected in at least one third of patients with VT.
Volkmann
H
H
Abteilung für Kardiologie und Angiologie, Friedrich-Schiller-Universität Jena.
Kühnert
H
H
Dannberg
G
G
Heinke
M
M
Leeder
U
U
Popp
U
U
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D003984:Dibenzazepines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004558:Electric Stimulation; D004562:Electrocardiography; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects; D006352:Heart Ventricles / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D013610:Tachycardia / Q000188:drug therapy* / Q000503:physiopathology
D000889:Anti-Arrhythmia Agents; D003984:Dibenzazepines; C048166:tiracizine
Elektrophysiologische und antiarrhythmische Effekte von Tiracizin bei ventrikulären Tachykardien.